INmune Bio (NASDAQ:INMB) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

INmune Bio (NASDAQ:INMB) released its quarterly earnings results on Monday. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.09, FiscalAI reports.

Here are the key takeaways from INmune Bio’s conference call:

• CORDStrom is the company’s lead value driver and the team says it will file a U.K. MAA by mid‑summer 2026 (with subsequent EMA and U.S. BLA filings later in 2026), supported by reproducible batch manufacturing, defined potency assays/MOA, and clinical data showing wound healing, itch reduction, QoL improvements and a favorable safety profile.
• While management highlights encouraging biomarker and subgroup signals for XPro and an FDA alignment on a two‑stage adaptive Phase III, the MINDFuL Phase II did not meet its top‑line primary endpoint (leading to a $16.5M intangible‑asset impairment) and the program will require additional partner funding to advance.
• The company reported $24.8M in cash at year‑end 2025 and believes this funds operations only through Q1 2027, implying near‑term financing or partnership needs given ongoing development plans and a net loss of $45.9M for 2025.
• INKmune’s Phase II in metastatic castration‑resistant prostate cancer was completed ahead of schedule and under budget, meeting its primary endpoint and two of three secondary endpoints, which management positions as de‑risking that program.

INmune Bio Stock Down 0.9%

INmune Bio stock opened at $1.13 on Wednesday. The company’s fifty day simple moving average is $1.39 and its 200-day simple moving average is $1.64. INmune Bio has a 12 month low of $1.09 and a 12 month high of $11.64. The stock has a market cap of $30.04 million, a P/E ratio of -0.59 and a beta of 0.77.

Analysts Set New Price Targets

Several research firms have issued reports on INMB. Wall Street Zen raised shares of INmune Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Lucid Cap Mkts upgraded INmune Bio from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, INmune Bio presently has a consensus rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers lifted its stake in shares of INmune Bio by 14.4% in the first quarter. Rhumbline Advisers now owns 19,153 shares of the company’s stock worth $150,000 after buying an additional 2,409 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in INmune Bio by 20.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock valued at $78,000 after acquiring an additional 8,427 shares during the period. Royal Bank of Canada grew its position in shares of INmune Bio by 44.8% in the first quarter. Royal Bank of Canada now owns 29,863 shares of the company’s stock valued at $233,000 after purchasing an additional 9,236 shares during the last quarter. Wells Fargo & Company MN grew its position in shares of INmune Bio by 79.0% in the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after purchasing an additional 10,970 shares during the last quarter. Finally, Intech Investment Management LLC bought a new position in shares of INmune Bio in the second quarter worth about $26,000. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.